$22.75
+0.90 (+4.12%)
Open$21.88
Previous Close$21.85
Day High$23.62
Day Low$21.42
52W High$31.18
52W Low$1.92
Volume—
Avg Volume521.4K
Market Cap1.38B
P/E Ratio—
EPS$-4.12
SectorBiotechnology
Analyst Ratings
Strong Buy
11 analysts
Price Target
-43.7% upside
Current
$22.75
$22.75
Target
$12.80
$12.80
$8.80
$12.80 avg
$18.52
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 639.02M | 671.15M | 526.83M |
| Net Income | 3.07M | 3.06M | 2.31M |
| Profit Margin | 0.5% | 0.5% | 0.4% |
| EBITDA | 3.98M | 4.67M | 3.27M |
| Free Cash Flow | 2.86M | 3.84M | 2.49M |
| Rev Growth | +2.1% | +18.5% | -6.0% |
| Debt/Equity | 0.55 | 0.45 | 0.49 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $207.18 | +0.96% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.93 | +1.58% | 24.4 | 188.06B |
| GILD | Gilead Sciences Inc | $138.26 | +0.11% | 20.0 | 170.34B |
| VRTX | Vertex Pharmaceuticals Inc | $454.97 | +1.42% | 29.2 | 115.53B |
| REGN | Regeneron Pharmaceuticals | $749.47 | +1.05% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.70 | +6.70% | 139.7 | 43.84B |